Aliqopa (copanlisib IV) Utilization Management Medical Policy
Customize your policy alerts
Sign up for Aspirus Arise POLICY: Oncology (Injectable) - Aliqopa Utilization Management Medical Policy alerts
Get alerted when POLICY: Oncology (Injectable) - Aliqopa Utilization Management Medical Policy changes without checking for updates manually.
Monitor payer policy activity
Defines prior authorization, coverage criteria, dosing, and restrictions for Aliqopa (copanlisib IV) for Aspirus Medicare Plans; applies to providers prescribing or requesting coverage for Aliqopa.
Policy notes Bayer voluntarily withdrew Aliqopa from the U.S. market and the FDA withdrawal of the NDA, and retains coverage pathways for patients currently receiving therapy.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.